<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药融圈 | wechat-feeds</title><link>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</link><description>药融圈PHARNEX汇聚数万医药大咖，得到数千家医药创业者鼎力支持，开展日常专题讲座。致力于成为“专业、前沿、权威、严谨”的医药行业资讯平台，以及项目、技术、工厂、融资、股权投资等资源整合平台。欢迎您关注药融圈，共同碰撞“药”的火花!</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 25 Feb 2021 11:54:37 +0800</pubDate><image><url>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</url><title>药融圈 | wechat-feeds</title><link>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>眼科火热：这款新药每周费用高达3.6万</title><link>https://mp.weixin.qq.com/s/5UNdvKgmZjSx1iXbv87JEg</link><description></description><content:encoded><![CDATA[眼科火热：这款新药每周费用高达3.6万]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>推动细胞内各类化学反应的催化剂，“酶”有话说</title><link>https://mp.weixin.qq.com/s/Q7aFXQpOuJgIyC0KJA6rcQ</link><description></description><content:encoded><![CDATA[推动细胞内各类化学反应的催化剂，“酶”有话说]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>药欣生物引进凯泰资本近亿元B1轮融资</title><link>https://mp.weixin.qq.com/s/PJtF53lVegO_se3xmI83MA</link><description></description><content:encoded><![CDATA[药欣生物引进凯泰资本近亿元B1轮融资]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>限时免费，大湾区生物医药创新者峰会参会报名破800</title><link>https://mp.weixin.qq.com/s/75hIYoY2llbkjKl_2fWLzg</link><description></description><content:encoded><![CDATA[限时免费，大湾区生物医药创新者峰会参会报名破800]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>Graviton Bioscience超5亿美元获得北京泰德ROCK2抑制剂海外权益</title><link>https://mp.weixin.qq.com/s/kJVC2WZ64VjgoAssmTD2QA</link><description></description><content:encoded><![CDATA[Graviton Bioscience超5亿美元获得北京泰德ROCK2抑制剂海外权益]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>刚完成1.3亿美元B轮融资，Day One引进两款默克开发的MEK1/2抑制剂</title><link>https://mp.weixin.qq.com/s/dt1Q2kqthnTFe_Agkh1NCg</link><description></description><content:encoded><![CDATA[刚完成1.3亿美元B轮融资，Day One引进两款默克开发的MEK1/2抑制剂]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>AmacaThera完成超额认购A轮融资，开发水凝胶技术平台产品</title><link>https://mp.weixin.qq.com/s/KfHjuGPHakuu7a9kVuIJqg</link><description></description><content:encoded><![CDATA[AmacaThera完成超额认购A轮融资，开发水凝胶技术平台产品]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>新产业：三项生化产品取得CE准入资格</title><link>https://mp.weixin.qq.com/s/X1XNUjTL0FjTjdwRmXQ3yw</link><description></description><content:encoded><![CDATA[新产业：三项生化产品取得CE准入资格]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>一文初识：日本CRO产业状况及Top 6排名</title><link>https://mp.weixin.qq.com/s/aF_Z7kt3xYbYdPqXPIbsnQ</link><description></description><content:encoded><![CDATA[一文初识：日本CRO产业状况及Top 6排名]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>限时免费，大湾区生物医药创新者峰会参会报名破700</title><link>https://mp.weixin.qq.com/s/0BBAAMSaB4_xuQADfKBSGQ</link><description></description><content:encoded><![CDATA[限时免费，大湾区生物医药创新者峰会参会报名破700]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>齐鲁、信达、君实......7款新药申请上市，73个品种过评，PD-1重磅品种新适应症获批，鼻咽癌迎来“零突破”</title><link>https://mp.weixin.qq.com/s/F1YNw6ie6I-STxMeYQ0SGg</link><description></description><content:encoded><![CDATA[齐鲁、信达、君实......7款新药申请上市，73个品种过评，PD-1重磅品种新适应症获批，鼻咽癌迎来“零突破”]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>重磅！礼进生物完成由IDG资本领投的数亿元人民币C轮融资</title><link>https://mp.weixin.qq.com/s/zKqGWVki1s49B1cC_DhrMA</link><description></description><content:encoded><![CDATA[重磅！礼进生物完成由IDG资本领投的数亿元人民币C轮融资]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>Novo Holdings宣布收购新药CRO/CDMO公司Altasciences</title><link>https://mp.weixin.qq.com/s/fq-EzKFatZ_zYpw9fhmd7Q</link><description></description><content:encoded><![CDATA[Novo Holdings宣布收购新药CRO/CDMO公司Altasciences]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>上药引进的PD-1抗体Prolgolimab进入III期临床</title><link>https://mp.weixin.qq.com/s/zdwDsKpy4Xp0KI2qZFj-5w</link><description></description><content:encoded><![CDATA[上药引进的PD-1抗体Prolgolimab进入III期临床]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>仙琚制药：醋酸泼尼松片一致性评价受理&amp;戊酸雌二醇片生产药品注册受理</title><link>https://mp.weixin.qq.com/s/r-LOBwJdTdGXH60uyCDNTg</link><description></description><content:encoded><![CDATA[仙琚制药：醋酸泼尼松片一致性评价受理&戊酸雌二醇片生产药品注册受理]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>医保局助力：银屑病克星IL-17苏金单抗，每支仅1198元</title><link>https://mp.weixin.qq.com/s/trkjhPKWLtd9lTnH4iDZpQ</link><description></description><content:encoded><![CDATA[医保局助力：银屑病克星IL-17苏金单抗，每支仅1198元]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>欧康维视低浓度阿托品滴眼液获FDA批准进入Ⅲ期临床，低浓度阿托品市场重磅玩家入局</title><link>https://mp.weixin.qq.com/s/AYFxhS6QJhRbIedAOp5R_A</link><description></description><content:encoded><![CDATA[欧康维视低浓度阿托品滴眼液获FDA批准进入Ⅲ期临床，低浓度阿托品市场重磅玩家入局]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>限时免费，大湾区生物医药创新者峰会参会报名破700</title><link>https://mp.weixin.qq.com/s/A7aIXI7fuMTr186rAdGOOw</link><description></description><content:encoded><![CDATA[限时免费，大湾区生物医药创新者峰会参会报名破700]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>来自东阳：低调API药企拟上市</title><link>https://mp.weixin.qq.com/s/LhQKUmfyGVuXS0BH3E-nBA</link><description></description><content:encoded><![CDATA[来自东阳：低调API药企拟上市]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>低调：绿谷创始人另一公司，景杰生物IPO在即</title><link>https://mp.weixin.qq.com/s/J3I2veIhTv4cJ1sd0Plpxg</link><description></description><content:encoded><![CDATA[低调：绿谷创始人另一公司，景杰生物IPO在即]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item></channel></rss>